InsiderTrades.com logo
James Paul Scopa net worth and biography
  • LinkedIn
  • Phone
  • Email
  • Website

James Scopa Biography and Net Worth

Director of DICE Therapeutics

Jim Scopa has more than 30 years of experience in the life sciences industry, investing in companies and advising public and private boards on strategic and financial transactions. From 2005 to 2017 he served as a managing director and a member of the investment committee of MPM Capital, a global life sciences venture capital firm. Prior to MPM, Mr. Scopa spent 18 years advising growth companies in biopharmaceuticals and medical devices principally at Deutsche Banc Alex. Brown and Thomas Weisel Partners. Mr. Scopa currently serves on the boards of Adverum Biotechnologies, Aligos Therapeutics, Blade Therapeutics and Neuron23, Inc., as well as on the investment committee of One Ventures. He previously served on the boards of Semma Therapeutics (sold to Vertex), True North Therapeutics (sold to BioVerativ) and iPierian (sold to Bristol Myers Squibb). In 2017, he was appointed a fellow in the Distinguished Careers Institute at Stanford. 

Mr. Scopa received an A.B. from Harvard College, an MBA from Harvard Business School and a J.D. from Harvard Law School.

What is James Paul Scopa's net worth?

The estimated net worth of James Paul Scopa is at least $475.50 thousand as of February 7th, 2024. Mr. Scopa owns 10,000 shares of DICE Therapeutics stock worth more than $475,500 as of December 5th. This net worth estimate does not reflect any other assets that Mr. Scopa may own. Learn More about James Paul Scopa's net worth.

How do I contact James Paul Scopa?

The corporate mailing address for Mr. Scopa and other DICE Therapeutics executives is 279 E. GRAND AVENUE SUITE 300 LOBBY B, SOUTH SAN FRANCISCO CA, 94080. DICE Therapeutics can also be reached via phone at 650-566-1420 and via email at [email protected]. Learn More on James Paul Scopa's contact information.

Has James Paul Scopa been buying or selling shares of DICE Therapeutics?

James Paul Scopa has not been actively trading shares of DICE Therapeutics during the last quarter. Most recently, James Paul Scopa sold 10,000 shares of the business's stock in a transaction on Friday, March 17th. The shares were sold at an average price of $29.05, for a transaction totalling $290,500.00. Following the completion of the sale, the director now directly owns 23,719 shares of the company's stock, valued at $689,036.95. Learn More on James Paul Scopa's trading history.

Who are DICE Therapeutics' active insiders?

DICE Therapeutics' insider roster includes Kevin Judice (Co-Founder & CEO), Richard Scheller (Chairman of the Board), and James Scopa (Director). Learn More on DICE Therapeutics' active insiders.

James Paul Scopa Insider Trading History at DICE Therapeutics

Transaction DateBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
3/17/2023Sell10,000$29.05$290,500.0023,719View SEC Filing Icon  
See Full Table

James Paul Scopa Buying and Selling Activity at DICE Therapeutics

This chart shows James Paul Scopa's buying and selling at DICE Therapeutics by year and by quarter.

Skip ChartChart Data in Insider Trading History Table

DICE Therapeutics Company Overview

DICE Therapeutics logo
DICE Therapeutics, Inc., a biopharmaceutical company, builds various oral therapeutic candidates to treat chronic diseases in immunology and other therapeutic areas. Its platform DELSCAPE is designed to discover selective oral small molecules to modulate protein-protein interactions as effectively as systemic biologics. The company's lead therapeutic candidate is DC-806, an oral antagonist of the pro-inflammatory signaling molecule, interleukin-17 (IL-17) that is a validated drug target implicated in a various immunology indications. It also develops DC-853, an oral IL-17 antagonist. In addition, the company is developing oral therapeutic candidates targeting alpha 4 beta 7 integrin for the treatment of inflammatory bowel diseases, as well as targeting alpha V beta 1/ alpha V beta 6 integrin for the treatment of idiopathic pulmonary fibrosis. Further, it focuses on programmed death-ligand 1 program, an immuno-oncology targeting antibody therapeutics. The company was founded in 2013 and is headquartered in South San Francisco, California.
Read More

Today's Range

Now: $47.55
Low: $47.55
High: $47.55

50 Day Range

MA: $47.31
Low: $46.62
High: $47.55

2 Week Range

Now: $47.55
Low: $15.08
High: $47.90

Volume

N/A

Average Volume

1,028,719 shs

Market Capitalization

$2.27 billion

P/E Ratio

N/A

Dividend Yield

N/A

Beta

1.03